摘要
目的 探讨重组人表皮细胞生长因子在乳腺癌根治术中的应用价值。方法 将乳腺癌患者 5 4例 ,随机分为两组。一组 ( 2 6例 )行常规乳腺癌根治术 ,另一组 ( 2 8例 )行常规乳腺癌根治术的同时应用重组人表皮细胞生长因子 ,通过观察有无皮瓣坏死及切口愈合时间确定重组人表皮细胞生长因子的作用。结果 应用重组人表皮细胞生长因子组 2 8例 ,平均切口愈合时间 18± 3天 ,无皮瓣坏死 ,对照组 2 6例 ,平均切口愈合时间 2 1± 5天 ,皮瓣坏死 8例 ,具有显著性差异 (P <0 .0 1)。结论 乳腺癌术后应用重组人表皮细胞生长因子可以有效预防皮瓣坏死 ,促进切口愈合。
Objective To evaluate the efficacy of rhEGF in radical mastectomy.Methods A prospective randomized trial was conducted consisting of 54 women. All women received radical mastectomy. At the completion of the mastectomy they were randomized to receive either standard closure or the application of rhEGF after standard closure. A total of 28 women received rhEGF and 26 received no rhEGF.Then all patients were monitored for flap necrosis and healing time of the incision. Results The rhEGF group ,which have no flap necrosis,were healed in a mean time of 18±3 days,while the control group has 8 case occurred and the mean healing time is 21±5 days.Conclusions Application of rhEGF can prevent flap necrosis efficiently in patients undergoing radical mastectomy.
出处
《海南医学》
CAS
2004年第10期12-12,14,共2页
Hainan Medical Journal
